Clinical characteristics of COVID-19 patients who received ventilator management during the omicron variant period in a tertiary hospital in Japan

Table 1.

Clinicalcharacteristics of 11 adult COVID-19 received with ventilator management

  Age M/F Ward Underlying diseases Vaccine Ag titer Bacteria Antivirals Antibiotics Steroid NAb ECMO Survive/Death

1 72 M ER COPD, Unknown 190 Hi RDV MEPM Dex STV None S
2 76 M ER COPD, Unknown 42.7 Hi, Ef RDV LSFX Dex None None S
3 79 M SCU Parkinson Dis Unknown 670 None RDV SBT/ABPC Dex None None Death
4 81 M ER Nursing home 5 3457 None RDV SBT/ABPC Dex STV None S
5 76 M ER CKD 6 2916 MSSA, Kp RDV MEPM Dex STV None S
6 72 M ER ALS 6 20912 E coli RDV MEPM Dex STV None S
7 55 M ER Brain tumor 3 15,4 MSSA RDV TAZ/PIP Dex None Positive S
8 85 M ER CHD None 4809 None RDV SBT/ABPC Dex None None Death
9 51 F ER Conversion Unknown 19.2 MRSA RDV LZD Dex STV Positive S
10 54 M ER None None 28.3 None RDV TAZ/PIPC Dex None Positive S
  Age M/F Ward Underlying diseases Vaccine Ag titer Bacteria Antivirals Antibiotics Steroid NAb ECMO Survive/Death

Abbreviations: M/F: male/female, ER: emergency department, SCU: stroke intensive care unit, COPD: chronic obstructive pulmonary disease, CKD: chronic kidney disease, ALS: amyotrophic lateral sclerosis, CHD: chronic heart disease, HD: hemodyalysis, Hi: Haemophilus influenzae, Ef: enterococcus faecalis, MSSA: methicillin susceptible Staphylococcus aureus, Kp: Klebsiella pneumoniae, MRSA: methicillin resistance Staphylococcus aureus, RDV: remdesivir, MEPM: meropenem, LVFX: levofloxacin, SBT/ABPC: sulbactam/ampicillin, TAZ/PIPC: tazobactam/piperacillin, LZD: linezolid, CFPM: cefepime, Dex: dexamethasone, N ab: neutralizing antibody, STV: sotrovimab, ECMO: extracorporeal membrane oxygenation, S: survive